ARTICLE | Company News

J&J opts in for Idorsia's hypertension candidate

December 8, 2017 4:20 AM UTC

Idorsia Ltd. (SIX:IDIA) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exercised its option to co-develop and commercialize aprocitentan (ACT-132577) and its derivatives.

Idorsia will be responsible for Phase III development and regulatory submission of aprocitentan to treat hypertension that is not controlled by at least 3 anti-hypertensive drugs, with costs shared equally by the partners. Janssen will have worldwide commercialization rights, and is responsible for developing the product in any additional indications...

BCIQ Company Profiles

Idorsia Ltd.

Johnson & Johnson

BCIQ Target Profiles

Endothelin receptor